Identification
NameBethanechol
Accession NumberDB01019  (APRD00051)
TypeSmall Molecule
GroupsApproved
Description

Bethanechol is a synthetic ester structurally and pharmacologically related to acetylcholine. A slowly hydrolyzed muscarinic agonist with no nicotinic effects, bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, cardiac rate changes, and bronchial spasms. [PubChem]

Structure
Thumb
Synonyms
(2-Hydroxypropyl)trimethylammonium carbamate
2-(Carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
2-Carbamoyloxypropyl-trimethylazanium
Amidopropyldimethylbetaine
Bethanechol
Carbamoyl-beta-methylcholine
carbamoyl-β-methylcholine
Carbamyl-beta-methylcholine
carbamyl-β-methylcholine
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Bethanechol ChlorideH4QBZ2LO84 590-63-6XXRMYXBSBOVVBH-UHFFFAOYNA-NDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Duvoid Tablets 10 mgTablet10 mgOralPaladin Labs Inc1992-12-31Not applicableCanada
Duvoid Tablets 25 mgTablet25 mgOralPaladin Labs Inc1992-12-31Not applicableCanada
Duvoid Tablets 50 mgTablet50 mgOralPaladin Labs Inc1992-12-31Not applicableCanada
Myotonachol Tablets 10mgTablet10 mgOralGlenwood Inc.1993-12-312010-07-16Canada
Myotonachol Tablets 25mgTablet25 mgOralGlenwood Inc.1993-12-312010-07-16Canada
PHL-bethanechol ChlorideTablet25 mgOralPharmel Inc1998-02-172016-10-25Canada
PHL-bethanechol ChlorideTablet10 mgOralPharmel Inc1998-02-172016-10-25Canada
PHL-bethanechol ChlorideTablet50 mgOralPharmel Inc1998-02-172016-10-25Canada
PMS-bethanechol Chloride Tab 10mgTablet10 mgOralPharmascience Inc1990-12-31Not applicableCanada
PMS-bethanechol Chloride Tab 25mgTablet25 mgOralPharmascience Inc1990-12-31Not applicableCanada
PMS-bethanechol Chloride Tab 50mgTablet50 mgOralPharmascience Inc1990-12-31Not applicableCanada
Urecholine Inj 5mg/mlLiquid5 mgSubcutaneousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312003-01-31Canada
Urecholine Tab 10mgTablet10 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312001-03-21Canada
Urecholine Tab 25mgTablet25 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312001-01-25Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bethanechol ChlorideTablet10 mg/1OralUpsher Smith Laboratories2010-01-24Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralWockhardt2003-09-29Not applicableUs64679 0966 01 nlmimage10 70463861
Bethanechol ChlorideTablet25 mg/1OralAv Pak2007-01-11Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralAvera Mc Kennan Hospital2015-03-19Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralLannett Company, Inc.2008-03-27Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralAmneal Pharmaceuticals of New York Llc2007-11-21Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralWockhardt2003-09-29Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2007-05-012016-11-15Us
Bethanechol ChlorideTablet10 mg/1OralMajor2010-04-01Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralGolden State Medical Supply2010-04-06Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralAmerincan Health Packaging2007-02-202016-04-30Us
Bethanechol ChlorideTablet10 mg/1OralLannett Company, Inc.2008-03-27Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2009-04-30Not applicableUs57664 0104 88 nlmimage10 0b0405b0
Bethanechol ChlorideTablet50 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2007-05-012016-11-15Us
Bethanechol ChlorideTablet25 mg/1OralMarlex Pharmaceuticals Inc2015-04-01Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralWockhardt2003-09-29Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralMajor2010-04-01Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralRising Pharmaceuticals2010-08-24Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralWockhardt2003-09-29Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralPliva, Inc.1990-09-30Not applicableUs50111 0325 01 nlmimage10 d32f69db
Bethanechol ChlorideTablet25 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2007-11-21Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralRising Pharmaceuticals2010-04-06Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralAvera Mc Kennan Hospital2015-06-15Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2009-04-30Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-11-21Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralAv Kare, Inc.2010-04-01Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralMajor2010-04-01Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralGolden State Medical Supply2010-04-06Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralUpsher Smith Laboratories2010-01-24Not applicableUs00832 0512 01 nlmimage10 534929c9
Bethanechol ChlorideTablet25 mg/1OralWockhardt2003-09-29Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralRemedy Repack2013-09-192016-12-30Us
Bethanechol ChlorideTablet5 mg/1OralPliva, Inc.1990-09-30Not applicableUs50111 0323 01 nlmimage10 aa2f556a
Bethanechol ChlorideTablet10 mg/1OralAmerincan Health Packaging2015-01-15Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralAmneal Pharmaceuticals of New York Llc2007-11-21Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralLannett Company, Inc.2008-03-27Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralWockhardt2003-09-29Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2007-05-012016-11-15Us
Bethanechol ChlorideTablet50 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2009-04-30Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-09-29Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralMarlex Pharmaceuticals Inc2015-04-01Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralRising Pharmaceuticals2010-04-06Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralPliva, Inc.1990-09-30Not applicableUs50111 0326 01 nlmimage10 9c2f4e4a
Bethanechol ChlorideTablet5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2007-11-21Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralAv Pak2007-01-11Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralAmneal Pharmaceuticals of New York Llc2007-11-21Not applicableUs
Bethanechol ChlorideTablet10 mg/1Oralbryant ranch prepack2010-04-06Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralGolden State Medical Supply2010-08-24Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralUpsher Smith Laboratories2010-01-24Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2007-05-012016-11-15Us
Bethanechol ChlorideTablet10 mg/1OralMarlex Pharmaceuticals Inc2015-04-01Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralGolden State Medical Supply2010-04-06Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralUpsher Smith Laboratories2010-01-24Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralWockhardt2003-09-29Not applicableUs64679 0968 01 nlmimage10 7939bc9d
Bethanechol ChlorideTablet25 mg/1OralPhysicians Total Care, Inc.1995-08-14Not applicableUs
Bethanechol ChlorideTablet10 mg/1OralPliva, Inc.1990-09-30Not applicableUs50111 0324 01 nlmimage10 a62f535a
Bethanechol ChlorideTablet25 mg/1OralAmerincan Health Packaging2015-01-06Not applicableUs65162 0573 10 nlmimage10 4b3fa5dd
Bethanechol ChlorideTablet50 mg/1OralAmneal Pharmaceuticals of New York Llc2007-11-21Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralLannett Company, Inc.2008-03-27Not applicableUs
Bethanechol ChlorideTablet50 mg/1OralWockhardt2003-09-29Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralRising Pharmaceuticals2010-04-06Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralAvera Mc Kennan Hospital2016-03-10Not applicableUs
Bethanechol ChlorideTablet5 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2009-04-30Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-09-29Not applicableUs
Bethanechol ChlorideTablet25 mg/1OralAv Kare, Inc.2010-04-01Not applicableUs
UrecholineTablet5 mg/1OralTeva Women's Health2001-02-01Not applicableUs51285 0697 02 nlmimage10 8e2f475a
UrecholineTablet25 mg/1OralTeva Women's Health2000-04-01Not applicableUs51285 0691 02 nlmimage10 5f2f2f89
UrecholineTablet50 mg/1OralTeva Women's Health2001-02-01Not applicableUs51285 0692 02 nlmimage10 8a2f454a
UrecholineTablet10 mg/1OralTeva Women's Health2001-02-01Not applicableUs51285 0690 02 nlmimage10 852f42da
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DuvoidRoberts
MyotonacholGlenwood
MyotonineNot Available
UrabethNot Available
Uro-CarbHamilton
Brand mixturesNot Available
Categories
UNII004F72P8F4
CAS number674-38-4
WeightAverage: 161.2221
Monoisotopic: 161.129002798
Chemical FormulaC7H17N2O2
InChI KeyNZUPCNDJBJXXRF-UHFFFAOYSA-O
InChI
InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1
IUPAC Name
1-(trimethylazaniumyl)propan-2-yl carbamate
SMILES
CC(C[N+](C)(C)C)OC(N)=O
Pharmacology
Indication

For the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.

Structured Indications
Pharmacodynamics

Bethanechol is a parasympathomimetic (cholinergic) used for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. Bethanechol, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine. It increases the tone of the detrusor urinae muscle, usually producing a contraction sufficiently strong to initiate micturition and empty the bladder. It stimulates gastric motility, increases gastric tone, and often restores impaired rhythmic peristalsis. Bethanechol chloride is not destroyed by cholinesterase and its effects are more prolonged than those of acetytcholine.

Mechanism of action

Bethanechol directly stimulates cholinergic receptors in the parasympathetic nervous system while stimulating the ganglia to a lesser extent. Its effects are predominantly muscarinic, inducing little effect on nicotinic receptors and negligible effects on the cardiovascular system.

TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M2Proteinyes
agonist
HumanP08172 details
Muscarinic acetylcholine receptor M1ProteinunknownNot AvailableHumanP11229 details
Muscarinic acetylcholine receptor M3ProteinunknownNot AvailableHumanP20309 details
Muscarinic acetylcholine receptor M4ProteinunknownNot AvailableHumanP08173 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Bethanechol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bethanechol.Approved
AlprenololThe risk or severity of adverse effects can be increased when Alprenolol is combined with Bethanechol.Approved, Withdrawn
AmbenoniumThe risk or severity of adverse effects can be increased when Ambenonium is combined with Bethanechol.Approved
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bethanechol.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bethanechol.Approved
BefunololThe risk or severity of adverse effects can be increased when Befunolol is combined with Bethanechol.Experimental
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bethanechol.Approved
BevantololThe risk or severity of adverse effects can be increased when Bevantolol is combined with Bethanechol.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bethanechol.Approved
BopindololThe risk or severity of adverse effects can be increased when Bopindolol is combined with Bethanechol.Approved
BucindololThe risk or severity of adverse effects can be increased when Bucindolol is combined with Bethanechol.Investigational
BufuralolThe risk or severity of adverse effects can be increased when Bufuralol is combined with Bethanechol.Experimental, Investigational
BupranololThe risk or severity of adverse effects can be increased when Bupranolol is combined with Bethanechol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bethanechol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Bethanechol.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Bethanechol.Approved, Investigational
CimetropiumBethanechol may decrease the anticholinergic activities of Cimetropium.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Decamethonium is combined with Bethanechol.Approved
DemecariumThe risk or severity of adverse effects can be increased when Demecarium is combined with Bethanechol.Approved
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Bethanechol.Approved
EchothiophateThe risk or severity of adverse effects can be increased when Echothiophate is combined with Bethanechol.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Edrophonium is combined with Bethanechol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bethanechol.Approved
GalantamineThe risk or severity of adverse effects can be increased when Galantamine is combined with Bethanechol.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Bethanechol.Approved
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Bethanechol.Approved, Nutraceutical
Huperzine AThe risk or severity of adverse effects can be increased when Huperzine A is combined with Bethanechol.Investigational
IndenololThe risk or severity of adverse effects can be increased when Indenolol is combined with Bethanechol.Withdrawn
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Bethanechol.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Bethanechol.Approved
LandiololThe risk or severity of adverse effects can be increased when Aop200704 is combined with Bethanechol.Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Bethanechol.Approved
MalathionThe risk or severity of adverse effects can be increased when Malathion is combined with Bethanechol.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Bethanechol.Approved
MemantineThe risk or severity of adverse effects can be increased when Memantine is combined with Bethanechol.Approved, Investigational
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Bethanechol.Investigational
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Bethanechol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bethanechol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Bethanechol.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Bethanechol.Approved
NeostigmineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Bethanechol.Approved, Vet Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bethanechol.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Bethanechol.Approved, Investigational
PhysostigmineThe risk or severity of adverse effects can be increased when Physostigmine is combined with Bethanechol.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Bethanechol.Approved
PractololThe risk or severity of adverse effects can be increased when Practolol is combined with Bethanechol.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bethanechol.Approved, Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Pyridostigmine is combined with Bethanechol.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Bethanechol.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bethanechol.Approved
TacrineThe risk or severity of adverse effects can be increased when Tacrine is combined with Bethanechol.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bethanechol.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Bethanechol.Approved
Food Interactions
  • Take on empty stomach: 1 hour before or 2 hours after meals to avoid nausea.
References
Synthesis Reference

Major, R.T. and Bonnett, H.T.; U.S. Patent 2,322,375: June 22,1943; assigned to Merck & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesN07AB02 — Bethanechol
AHFS Codes
  • 12:04.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.1 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedTreatmentEsophageal Dysmotility1
2TerminatedTreatmentEosinophilic Esophagitis (EoE)1
4Not Yet RecruitingPreventionBladder Dysfunction1
Pharmacoeconomics
Manufacturers
  • Sun pharmaceutical industries inc
  • Odyssey pharmaceuticals inc
  • Able laboratories inc
  • Actavis totowa llc
  • Amneal pharmaceutical
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Emcure pharmaceuticals usa inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lannett holdings inc
  • Lannett co inc
  • Pharmax group inc
  • Sandoz inc
  • Upsher smith laboratories inc
  • Watson laboratories inc
  • Wockhardt ltd
  • Wellspring pharmaceutical corp
  • Glenwood inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral25 mg/1
TabletOral5 mg/1
TabletOral50 mg/1
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
LiquidSubcutaneous5 mg
Prices
Unit descriptionCostUnit
Bethanechol chloride powder10.1USD g
Urecholine 50 mg tablet3.95USD tablet
Urecholine 25 mg tablet3.46USD tablet
Bethanechol Chloride 50 mg tablet2.97USD tablet
Bethanechol 50 mg tablet2.85USD tablet
Bethanechol Chloride 25 mg tablet1.86USD tablet
Urecholine 10 mg tablet1.85USD tablet
Bethanechol 25 mg tablet1.78USD tablet
Bethanechol Chloride 10 mg tablet1.39USD tablet
Bethanechol 10 mg tablet1.34USD tablet
Urecholine 5 mg tablet1.14USD tablet
Bethanechol Chloride 5 mg tablet0.74USD tablet
Bethanechol 5 mg tablet0.71USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)about 220Major, R.T. and Bonnett, H.T.; U.S. Patent 2,322,375: June 22,1943; assigned to Merck & Co., Inc.
water solubility10 mg/mL (chloride salt)Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.311 mg/mLALOGPS
logP-2.8ALOGPS
logP-4.1ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)15.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity54.44 m3·mol-1ChemAxon
Polarizability17.73 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8407
Blood Brain Barrier+0.9789
Caco-2 permeable+0.5251
P-glycoprotein substrateNon-substrate0.7295
P-glycoprotein inhibitor INon-inhibitor0.9508
P-glycoprotein inhibitor IINon-inhibitor0.8371
Renal organic cation transporterNon-inhibitor0.9209
CYP450 2C9 substrateNon-substrate0.8304
CYP450 2D6 substrateNon-substrate0.8066
CYP450 3A4 substrateSubstrate0.5216
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9522
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9047
Ames testNon AMES toxic0.6804
CarcinogenicityCarcinogens 0.522
BiodegradationNot ready biodegradable0.8058
Rat acute toxicity2.7833 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9852
hERG inhibition (predictor II)Non-inhibitor0.8915
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as tetraalkylammonium salts. These are organonitrogen compounds containing a quaternary ammonium substituted with four alkyl chains.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic nitrogen compounds
Sub ClassOrganonitrogen compounds
Direct ParentTetraalkylammonium salts
Alternative ParentsCarboximidic acids and derivatives / Organopnictogen compounds / Organooxygen compounds / Organic salts / Imines / Hydrocarbon derivatives / Amines / Organic cations
SubstituentsTetraalkylammonium salt / Carboximidic acid derivative / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organic salt / Organooxygen compound / Imine / Amine / Organic cation
Molecular FrameworkAliphatic acyclic compounds
External Descriptorscarbamate ester, quaternary ammonium ion (CHEBI:3084 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Agrawal A, Hila A, Tutuian R, Mainie I, Castell DO: Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J Clin Gastroenterol. 2007 Apr;41(4):366-70. [PubMed:17413603 ]
  4. Buranakarl C, Kijtawornrat A, Angkanaporn K, Komolvanich S, Bovee KC: Effects of bethanechol on canine urinary bladder smooth muscle function. Res Vet Sci. 2001 Dec;71(3):175-81. [PubMed:11798291 ]
  5. Cruzblanca H: An M2-like muscarinic receptor enhances a delayed rectifier K+ current in rat sympathetic neurones. Br J Pharmacol. 2006 Oct;149(4):441-9. Epub 2006 Sep 4. [PubMed:16953191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S: Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. [PubMed:9224827 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S: Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. [PubMed:9224827 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S: Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. [PubMed:9224827 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:55